ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across ...
AEON Biopharma, Inc. ( AEON) announced positive results from a pilot forced degradation study comparing ABP-450 with BOTOX (onabotulinumtoxinA), adding to the analytical evidence supporting the ...
The U.S. Food and Drug Administration (FDA) issued new draft guidance on October 29, 2025, proposing what it said were “major updates to simplify biosimilarity studies and reduce unnecessary clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results